Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
Close

Search

  • https://www.facebook.com/
  • https://twitter.com/
  • https://t.me/
  • https://www.instagram.com/
  • https://youtube.com/
Subscribe
Home/Latest News/Breakthrough Nine-Year Gene Therapy Results Transforming Haemophilia B Lives
Breakthrough Nine-Year Gene Therapy Results Transforming Haemophilia B Lives
Latest News

Breakthrough Nine-Year Gene Therapy Results Transforming Haemophilia B Lives

By adminitfy
February 6, 2026 2 Min Read

Nine-year follow-up data indicate that adeno-associated virus (AAV) gene therapy for haemophilia B offers sustained clinical benefits alongside a favorable long-term safety profile. However, the enhancement of full viral capsids did not show a significant improvement in outcomes. These results were highlighted at the 2026 Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), where they were awarded the top poster distinction.

Haemophilia B is a rare inherited bleeding disorder caused by a deficiency in factor IX, leading to recurrent bleeding and dependence on lifelong prophylactic replacement therapy. Previous studies on the scAAV2/8-LP1-hFIXco gene therapy revealed stable expression of factor IX and no long-term toxicity for over a decade. Nevertheless, some patients receiving higher doses experienced transient elevations in liver enzymes. To mitigate concerns regarding the immunogenicity linked to high capsid loads, a modified vector preparation enriched for full AAV capsids was developed and scrutinized.

In a study involving four adults with severe haemophilia B, a single intravenous infusion of the enriched vector was administered between 2014 and 2017, with a median follow-up of 9.8 years. Throughout the study, 47 treatment-related adverse events occurred, all of which were mild. Transient grade one transaminitis was noted in three participants early post-infusion, but no serious adverse events, factor IX inhibitors, thrombosis, or ongoing liver abnormalities were recorded during the follow-up.

Factor IX activity levels were dose-dependent, showing median values of 2% in the lower-dose group and 13.4% in the higher-dose group. Although factor IX levels decreased in the higher-dose group over time, they stabilized within a clinically relevant range. Two participants completely halted their prophylactic factor replacement, while the other two resumed treatment.

Significant improvements were noted among all participants. The mean annualized bleeding rate dropped from 11.6 before treatment to 3.2 during follow-up, and the average annual factor concentrate use decreased from 2,589 IU/kg to 1,301 IU/kg. The most substantial and sustained benefits were observed in the two participants who discontinued prophylaxis, demonstrating considerable long-term reductions in both bleeding episodes and factor use.

Overall, the findings affirm the long-term safety of systemic gene therapy for haemophilia B. Nonetheless, the enrichment for full AAV capsids did not lead to a noticeable decrease in liver toxicity or improve the durability of factor IX expression compared to earlier vector preparations.

Reiss UM and colleagues presented these findings, titled “9-year outcomes of scAAV2/8-LP1-hFIXco enriched for full AAV capsids in adults with severe hemophilia B,” as part of Abstract PO041 at the EAHAD 2026 Annual Meeting held from February 3 to 6, 2026.

Original Source: https://www.emjreviews.com/hematology/news/eahad-2026-nine-year-outcomes-of-gene-therapy/
Category:
Tags:
Publish Date: 2026-02-06 20:32:00

Author

adminitfy

Follow Me
Other Articles
Previous

Stay Ahead: Exciting Live Updates on Today’s Stock Market!

Next

Transform Your Health: Discover How SGLT2 Inhibitors Slash 5-Year Risks of CKD and Acute Kidney Injury in Type 2 Diabetes

No Comment! Be the first one.

Leave a Reply Cancel reply

You must be logged in to post a comment.

Search...

Recent Posts

  • Satellite Imagery Exposes China’s Medog Hydropower River Diversion
    Satellite Imagery Exposes China’s Medog Hydropower River Diversion
    by adminitfy
    November 22, 2026
  • Empowering Northeast India: CII’s CSR Connect Event Ignites Social Development
    by adminitfy
    July 3, 2024
  • Urgent Crisis: Northeast on High Alert as Death Toll Tragically Rises in Assam
    by adminitfy
    July 3, 2024
  • Triumphant Breakthrough: Security Forces Successfully Capture 4 Insurgents in Manipur Operation
    by adminitfy
    July 3, 2024

Welcome to the ultimate source for fresh perspectives! Explore curated content to enlighten, entertain and engage global readers.

  • Facebook
  • X
  • Instagram
  • LinkedIn

Latest Posts

  • Satellite Imagery Exposes China’s Medog Hydropower River Diversion
  • Assam Congress to Hold ‘Save Constitution’ March in Guwahati Nov 26
  • Nepal PM Balen Shah Seeks $2B India Package Before Modi Meeting
  • Gunotsav 2027: Assam Govt Revises Schedule, Assessment Begins Jan 6
  • Pawan Kalyan Orders Probe Into Jana Sena Activist’s Death
  • November 2026 (697)
  • October 2026 (646)
  • September 2026 (524)
  • August 2026 (1001)
  • July 2026 (986)
  • June 2026 (963)
  • May 2026 (922)
  • April 2026 (1525)
  • March 2026 (1522)
  • February 2026 (1252)
  • January 2026 (968)
  • December 2025 (942)
  • November 2025 (853)
  • October 2025 (869)
  • September 2025 (733)
  • August 2025 (810)
  • July 2025 (720)
  • June 2025 (1244)
  • May 2025 (2201)
  • April 2025 (1481)
  • March 2025 (2020)
  • February 2025 (1159)
  • January 2025 (1440)
  • December 2024 (1499)
  • November 2024 (1771)
  • October 2024 (1815)
  • September 2024 (1750)
  • August 2024 (1458)
  • July 2024 (1268)

Contact

Email

info@itfy.in

Location

INDIA

Copyright 2026 — Itfy.in. All rights reserved.